John Cox
CIK 1498428 · CEO & President · last filed 2026-09-08
John Cox is a CEO & President who has filed 85 SEC Form 4 insider transactions across 5 companies since 2010. The most recent filing, for DYN, was dated Nov 13, 2026. Across all open-market trades the lifetime net is −$13.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $16.7M across reported positions. 37 SEC filings were submitted jointly with BIOGEN INC. 10 Form 144 notices of planned sales are also on file; the latest, for DYN on Nov 13, 2026, lists the filer as an officer.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BIIB price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
225 SECOND AVENUE
WALTHAM, MA 02451
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DYN | CEO & President | 429,507 | $16.04 | $6.89M | $1.39M | 15 | 2026-09-08 |
| Sigilon Therapeutics, Inc. (SGTX) Delisted | Director | 342 | $22.47 | $7.7K | $0 | 5 | 2023-08-11 |
| RGEN | Director | 923 | $170.09 | $157.0K | -$4.07M | 10 | 2020-03-26 |
| Bioverativ Inc. (BIVV) Delisted | Chief Executive Officer | 0 | — | — | $0 | 9 | 2018-03-08 |
| BIIB | EVP Pharmaceutical Oper & Tech | 39,045 | $246.51 | $9.63M | -$10.66M | 36 | 2016-04-05 |
Holdings By Holder
| Symbol | Holder | Shares | Share of Total | Reported |
|---|---|---|---|---|
| DYN | Direct | 357,507 | 83.2% | 2026-09-08 |
| By Trust #3 | 18,000 | 4.2% | 2026-09-08 | |
| By Trust #2 | 18,000 | 4.2% | 2026-09-08 | |
| By Trust #1 | 18,000 | 4.2% | 2026-09-08 | |
| By Trust #4 | 18,000 | 4.2% | 2026-09-08 | |
| Total | 429,507 | |||
| SGTX | Direct | 0 | 0.0% | 2023-08-11 |
| John Gilbert Cox Living Trust dated 6/23/2006 See Footnote |
342 | 100.0% | 2020-12-10 | |
| Total | 342 |
Recent Filings
85 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-11-13 | DYN | Notice (144) Officer · Planned Nov 13, 2026 No sale on file yet |
−5,513 | -$92.8K | EDGAR |
| 2026-09-08 | DYN | Notice (144) Officer · Planned Sep 8, 2026 Sold: Form 4 filed Sep 8, 2026 |
−5,658 | -$106.8K | EDGAR |
| 2026-09-08 | DYN | Sell (S)10b5-1 Plan adopted Dec 4, 2024 |
−5,658 | -$106.8K | EDGAR |
| 2026-08-17 | DYN | Sell (S)10b5-1 Plan adopted Feb 12, 2026 |
−4,986 | -$131.0K | EDGAR |
| 2026-08-13 | DYN | Notice (144) Officer · Planned Aug 13, 2026 Sold: Form 4 filed Aug 17, 2026 |
−4,986 | -$131.0K | EDGAR |
| 2026-06-17 | DYN | Sell (S)10b5-1 Plan adopted Dec 4, 2024 |
−2,683 | -$49.2K | EDGAR |
| 2026-06-16 | DYN | Notice (144) Officer · Planned Jun 16, 2026 Sold: Form 4 filed Jun 17, 2026 |
−2,683 | -$49.2K | EDGAR |
| 2026-05-14 | DYN | Sell (S)10b5-1 Plan adopted Feb 12, 2026 |
−3,311 | -$60.8K | EDGAR |
| 2026-05-13 | DYN | Notice (144) Officer · Planned May 13, 2026 Sold: Form 4 filed May 14, 2026 |
−3,311 | -$60.8K | EDGAR |
| 2026-03-06 | DYN | Sell (S)10b5-1 Plan adopted Dec 4, 2024 |
−2,732 | -$40.7K | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).